Journal of Cardiovascular Imaging

Korean Society of Echocardiography (한국심초음파학회)
권호 표지
DOI QR코드

DOI QR Code

Antihypertensive Treatment in Severe Aortic Stenosis

  • Kang, Tae Soo (Division of Cardiology, Dankook University Hospital, Dankook University College of Medicine) ;
  • Park, Sungha (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine)
  • Received : 2018.05.13
  • Accepted : 2018.06.05
  • Published : 2018.06.27
⟨ Previous Next ⟩

Abstract

Previously, antihypertensive treatment in severe aortic stenosis was considered a relative contraindication. However, recent studies have shown that antihypertensive treatment may be safe and even beneficial in terms of reducing the progression of left ventricular pressure overload and even retarding the progression of valvular aortic stenosis. To date, no randomized clinical trials have been performed and no definite treatment guideline exist for the proper antihypertensive regimens. Antihypertensive treatment with ${\beta}-blockers$ has generally been avoided in patients with severe aortic stenosis (AS) due to the concerns for inducing left ventricular dysfunction and hemodynamic compromise in the presence of severe outflow tract obstruction. Although it remains unclear whether antihypertensive treatment with a ${\beta}-blockers$ is associated with increased risk of cardiovascular events in patients with AS, recent studies have shown that the use of ${\beta}-blockers$ may be safe and may even be beneficial. Renin-angiotensin system (RAS) are upregulated in AS and have been shown to be involved in valve calcification and progression in both experimental models and in human trials. As such, theoretically, RAS inhibition would have benefit in retarding the progression of valvular stenosis as well as have benefit in left ventricle remodeling. Recent clinical studies are indeed showing that use of RAS inhibition may be beneficial in patients with AS. Future clinical trials to establish the ideal target blood pressure and antihypertensive regimens in severe AS is essential.

Keywords

References

  1. Mozaffarian D, Benjamin EJ, Go AS, et al.American Heart Association Statistics CommitteeStroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016;133:e38-360. https://doi.org/10.1161/CIR.0000000000000350
  2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11. https://doi.org/10.1016/S0140-6736(06)69208-8
  3. Rossebo AB, Pedersen TR, Boman K, et al.SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. https://doi.org/10.1056/NEJMoa0804602
  4. Tastet L, Capoulade R, Clavel MA, et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study. Eur Heart J Cardiovasc Imaging 2017;18:70-8. https://doi.org/10.1093/ehjci/jew013
  5. Cramariuc D, Cioffi G, Rieck AE, et al. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovasc Imaging 2009;2:390-9. https://doi.org/10.1016/j.jcmg.2008.12.021
  6. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 2005;46:291-8. https://doi.org/10.1016/j.jacc.2004.10.081
  7. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54:1003-11. https://doi.org/10.1016/j.jacc.2009.04.079
  8. Nishimura RA, Otto CM, Bonow RO, et al.ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:e521-643. https://doi.org/10.1161/CIR.0000000000000031
  9. Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circ Res 2013;113:223-37. https://doi.org/10.1161/CIRCRESAHA.111.300084
  10. Marquis-Gravel G, Redfors B, Leon MB, Genereux P. Medical treatment of aortic stenosis. Circulation 2016;134:1766-84. https://doi.org/10.1161/CIRCULATIONAHA.116.023997
  11. Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS). Circulation 2016;134:455-68. https://doi.org/10.1161/CIRCULATIONAHA.115.021213
  12. Iwata S, Russo C, Jin Z, et al. Higher ambulatory blood pressure is associated with aortic valve calcification in the elderly: a population-based study. Hypertension 2013;61:55-60. https://doi.org/10.1161/HYPERTENSIONAHA.112.202697
  13. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg 2006;82:2116-22. https://doi.org/10.1016/j.athoracsur.2006.07.043
  14. Ngo DT, Stafford I, Sverdlov AL, et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol 2011;162:722-32. https://doi.org/10.1111/j.1476-5381.2010.01084.x
  15. O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-62. https://doi.org/10.1001/archinte.165.8.858
  16. Bang CN, Greve AM, Kober L, et al. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int J Cardiol 2014;175:492-8. https://doi.org/10.1016/j.ijcard.2014.06.013
  17. Chockalingam A, Venkatesan S, Subramaniam T, et al.Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004;147:E19.
  18. Dalsgaard M, Iversen K, Kjaergaard J, et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. Am Heart J 2014;167:226-34. https://doi.org/10.1016/j.ahj.2013.11.002
  19. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging 2015;16:834-41. https://doi.org/10.1093/ehjci/jev043
  20. Capoulade R, Clavel MA, Mathieu P, et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest 2013;43:1262-72. https://doi.org/10.1111/eci.12169
  21. Bang CN, Greve AM, Rossebo AB, et al. Antihypertensive treatment with ${\beta}$-blockade in patients with asymptomatic aortic stenosis and association with cardiovascular events. J Am Heart Assoc 2017;6:e006709. https://doi.org/10.1161/JAHA.117.006709
  22. Rossi A, Temporelli PL, Cicoira M, et al. Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis. Int J Cardiol 2015;190:15-7. https://doi.org/10.1016/j.ijcard.2015.04.083
  23. Hansson NH, Sorensen J, Harms HJ, et al. Metoprolol reduces hemodynamic and metabolic overload in asymptomatic aortic valve stenosis patients: a randomized trial. Circ Cardiovasc Imaging 2017;10:e006557. https://doi.org/10.1161/CIRCIMAGING.117.006557
  24. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:e127-e248. https://doi.org/10.1016/j.jacc.2017.11.006
  25. Broch K, Urheim S, Lonnebakken MT, et al. Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. Heart 2016;102:191-7. https://doi.org/10.1136/heartjnl-2015-308416
  26. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003;348:1756-63. https://doi.org/10.1056/NEJMoa022021
  27. Eleid MF, Nishimura RA, Sorajja P, Borlaug BA. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation 2013;128:1349-53. https://doi.org/10.1161/CIRCULATIONAHA.113.003071
  28. Little SH, Chan KL, Burwash IG. Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. Heart 2007;93:848-55. https://doi.org/10.1136/hrt.2006.098392
  29. Lloyd JW, Nishimura RA, Borlaug BA, Eleid MF. Hemodynamic response to nitroprusside in patients with low-gradient severe aortic stenosis and preserved ejection fraction. J Am Coll Cardiol 2017;70:1339-48. https://doi.org/10.1016/j.jacc.2017.07.736
  30. Mack MJ, Leon MB, Smith CR, et al.PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015;385:2477-84. https://doi.org/10.1016/S0140-6736(15)60308-7
  31. Douglas PS, Hahn RT, Pibarot P, et al. Hemodynamic outcomes of transcatheter aortic valve replacement and medical management in severe, inoperable aortic stenosis: a longitudinal echocardiographic study of cohort B of the PARTNER trial. J Am Soc Echocardiogr 2015;28:210-217.e1-9. https://doi.org/10.1016/j.echo.2014.10.009
  32. Perlman GY, Loncar S, Pollak A, et al. Post-procedural hypertension following transcatheter aortic valve implantation: incidence and clinical significance. JACC Cardiovasc Interv 2013;6:472-8. https://doi.org/10.1016/j.jcin.2012.12.124
  33. Dahl JS, Videbaek L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol 2010;106:713-9. https://doi.org/10.1016/j.amjcard.2010.04.028
  34. Goel SS, Aksoy O, Gupta S, et al. Renin-angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study. Ann Intern Med 2014;161:699-710. https://doi.org/10.7326/M13-1505

Cited by

  1. Cellular and molecular mechanisms of calcific aortic valve disease vol.2019, pp.9, 2018, https://doi.org/10.15829/1560-4071-2019-9-86-91
  2. Österreichischer Blutdruckkonsens 2019 vol.131, pp.suppl6, 2018, https://doi.org/10.1007/s00508-019-01565-0
  3. Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation vol.17, pp.11, 2018, https://doi.org/10.11909/j.issn.1671-5411.2020.11.002
  4. Antihypertensive therapy in patients with moderate to severe aortic stenosis vol.46, pp.9, 2018, https://doi.org/10.1097/01.npr.0000769732.71640.4c
  5. Low Relative Valve Load is Associated With Paradoxical Low-Flow Aortic Stenosis Despite Preserved Left Ventricular Ejection Fraction and Adverse Clinical Outcomes vol.31, pp.1, 2018, https://doi.org/10.1016/j.hlc.2021.05.075